JACC. Case reports · 2026
Renal Denervation for Uncontrolled Hypertension in a Patient With Mast Cell Activation Syndrome.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Nuvvula Sri, Mian Maryyam, Singh Avneet, Diamond Joseph
Аннотация
BACKGROUND: Renal denervation (RDN) is a treatment option for resistant hypertension.
CASE SUMMARY: We present a 64-year-old woman with medication intolerance secondary to mast cell activation syndrome who presented with uncontrolled hypertension and underwent bilateral RDN. Her systolic and diastolic recordings measured using Dinamap device (GE Healthcare), decreased from 151 ± 7.6 and 75 ± 4.1 mm Hg to 126 ± 4.5 and 66 ± 2.8 mm Hg, respectively, at 3 months after her procedure (both P < 0.05).
DISCUSSION: We show that RDN can be used in patients with severe medication intolerance due to an autoimmune condition. We also highlight the utility of using office-automated testing, which allowed us to likely obtain more accurate multiple blood pressure readings over 15 minutes.
TAKE-HOME MESSAGE: This report highlights RDN's efficacy in a patient unable to tolerate pharmacological antihypertensive therapy and highlights the clinical utility of using automated blood pressure readings.
CASE SUMMARY: We present a 64-year-old woman with medication intolerance secondary to mast cell activation syndrome who presented with uncontrolled hypertension and underwent bilateral RDN. Her systolic and diastolic recordings measured using Dinamap device (GE Healthcare), decreased from 151 ± 7.6 and 75 ± 4.1 mm Hg to 126 ± 4.5 and 66 ± 2.8 mm Hg, respectively, at 3 months after her procedure (both P < 0.05).
DISCUSSION: We show that RDN can be used in patients with severe medication intolerance due to an autoimmune condition. We also highlight the utility of using office-automated testing, which allowed us to likely obtain more accurate multiple blood pressure readings over 15 minutes.
TAKE-HOME MESSAGE: This report highlights RDN's efficacy in a patient unable to tolerate pharmacological antihypertensive therapy and highlights the clinical utility of using automated blood pressure readings.